Fengshuo Zhang, Yicong Meng, Bohan Zhao, Ziang Li, Mengran Han, Ming Li et al. Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine. // Clinical Drug Investigation. – 2025. – DOI: 10.1007/s40261-025-01484-1. – URL: https://doi.org/10.1007/s40261-025-01484-1
Fengshuo Zhang, Yicong Meng, Bohan Zhao, Ziang Li, Mengran Han, Ming Li, & Yun Zhou (2025). Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01484-1
Fengshuo Zhang, et al. “Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine.” Clinical Drug Investigation, 2025. doi:10.1007/s40261-025-01484-1.
@article{Zhang2025,
title = {Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine},
author = {Zhang, Fengshuo and Meng, Yicong and Zhao, Bohan and Li, Ziang and Han, Mengran and Li, Ming and Zhou, Yun},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01484-1},
url = {https://doi.org/10.1007/s40261-025-01484-1}
}